Alendronic Acid (Alendronate)
Brand names: Fosamax, Binosto
Alendronic acid (alendronate) is an oral nitrogen-containing bisphosphonate, first-line for the treatment and prevention of osteoporosis and for glucocorticoid-induced bone loss.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds avidly to bone mineral and is taken up by osteoclasts, where it inhibits the enzyme farnesyl pyrophosphate synthase, impairing osteoclast function and reducing bone resorption.
Prescribing in practice
- To prevent serious oesophageal injury it must be taken on rising with a full glass of plain water, and the patient must remain upright and not lie down or eat until after the post-dose interval; it is contraindicated in oesophageal abnormalities or inability to stay upright.
- Correct hypocalcaemia and vitamin D deficiency before starting, and ensure adequate calcium and vitamin D intake during treatment.
- Counsel on the rare risks of osteonecrosis of the jaw and atypical femoral fracture, and assess dental health before and during therapy.
Monitoring
Monitor renal function and calcium status, reassess fracture risk periodically and review the need for a treatment break (drug holiday) after several years.
Counselling the patient
- Take first thing in the morning with plain water only, then stay upright and avoid food and other medicines until after the recommended interval.
- Report any difficulty or pain on swallowing, heartburn, or new thigh, hip or groin pain.
- Maintain good oral hygiene and tell your dentist you take this medicine.
Evidence & guidelines
Fracture-prevention efficacy is supported by the FIT trials and reflected in NICE osteoporosis guidance.
Reference: NICE CG146 Osteoporosis; NOGG Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- Corrected Reticulocyte Count / Reticulocyte Production Index · Anaemia
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5